Provention Bio (Provention Bio) EPS (Diluted) : $-1.53 (TTM As of Dec. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Provention Bio EPS (Diluted)?

Provention Bio's Earnings per Share (Diluted) for the three months ended in Dec. 2022 was $-0.38. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-1.53.

Provention Bio's EPS (Basic) for the three months ended in Dec. 2022 was $-0.38. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2022 was $-1.53.

Provention Bio's EPS without NRI for the three months ended in Dec. 2022 was $-0.38. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022 was $-1.53.

During the past 3 years, the average EPS without NRIGrowth Rate was -12.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -34.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Provention Bio's highest 3-Year average EPS without NRI Growth Rate was -12.80% per year. The lowest was -88.90% per year. And the median was -15.00% per year.

Provention Bio EPS (Diluted) Historical Data

The historical data trend for Provention Bio's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provention Bio EPS (Diluted) Chart

Provention Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Diluted)

Get a 7-Day Free Trial

-1.19

-1.06

-1.88

-1.81

-1.52

Provention Bio Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
EPS (Diluted)	Get a 7-Day Free Trial															-0.41	-0.35	-0.46	-0.34	-0.38

Competitive Comparison of Provention Bio's EPS (Diluted)

For the Biotechnology subindustry, Provention Bio's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Provention Bio's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provention Bio's PE Ratio distribution charts can be found below:

* The bar in red indicates where Provention Bio's PE Ratio falls into.

Provention Bio EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Provention Bio's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-113.565	-	0)	/	74.723
	=	-1.52

Provention Bio's Diluted EPS for the quarter that ended in Dec. 2022 is calculated as

Diluted EPS (Q: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-33.277	-	0)	/	87.440
	=	-0.38

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.53

Provention Bio (NAS:PRVB) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Provention Bio EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Provention Bio's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Provention Bio (Provention Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provention Bio Inc (NAS:PRVB) » Definitions » EPS (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

55 Broad Street, 2nd Floor, Red Bank, NJ, USA, 07701

Website

https://www.proventionbio.com

Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases. The company's product candidates include PRV-031, for the interception, delay, or prevention of type 1 diabetes; PRV-3279, for the potential treatment of systemic lupus erythematosus; and PRV-101.

Executives

Sessa Capital (master), L.p.	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Ashleigh Palmer	director, 10 percent owner, officer: President and CEO	PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Francisco Leon	director, 10 percent owner, officer: Chief Scientific Officer	C/O PROVENTION BIO, INC., 110 OLD DRIFTWAY LANE, LEBANON NJ 08833
Jason Hoitt	officer: Chief Commercial Officer	C/O DOVA PHARMACEUTICALS, INC., 240 LEIGH FARM ROAD, SUITE 245, DURHAM NC 27707
Justin Vogel	officer: Chief Accounting Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Sarah O'brien	officer: Chief People Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, RED BANK NJ 07701
Sessa Capital Im, L.p.	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc	10 percent owner	888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Miyoko Christina Yi	officer: Chief Operations Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701
Benedict Osorio	officer: Chief Quality Officer	ONE WORLD TRADE CENTER, 47TH FLOOR, SUITE J, NEW YORK NY 10007
Eleanor Ramos	officer: Chief Medical Officer & COO	ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE E, SEATTLE WA 98102
Thierry Chauche	officer: Chief Financial Officer	C/O PROVENTION BIO, INC., 55 BROAD STREET, 2ND FLOOR, RED BANK NJ 07701